Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Emily E Holladay und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Urate Oxidase, Gout, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, Horizon Therapeutics (now Amgen Inc.), National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
The objective of this study was to ascertain pegloticase persistence and adverse events associated with concomitant immunomodulatory drug treatment in patients with gout.
Methods
We conducted a retrospective analysis of patients with gout using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry from January 2016 through June 2020. The first pegloticase infusion defined the index date. Based on concomitant immunomodulatory drug treatment, we identified three exposure groups: (1) immunomodulatory drug initiators (patients initiating an immunomodulatory prescription ±60 days from the index date), (2) prevalent immunomodulatory drug recipients (patients receiving their first immunomodulatory drug prescription >60 days before the index date with at least one prescription within ±60 days of the index date), and (3) immunomodulatory nonrecipients (patients receiving pegloticase without concomitant immunomodulatory drugs). We calculated the proportion of patients who achieved serum urate levels ≤6 mg/dL and who had laboratory abnormalities (white blood cell count
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham.
- University of Nebraska Medical Center and the VA Nebraska-Western Iowa Health Care System, Omaha.
- Amgen Inc, Thousand Oaks, California.
ORCID-Profile: Emily E Holladay, Ken Saag, Huifeng Yun, Brian LaMoreaux, Megan Francis-Sedlak, Jeffrey R Curtis
Förderung
- NIAMS NIH HHS
- Horizon Therapeutics (now Amgen Inc.)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Holladay, E. E., Mudano, A. S., Xie, F., Zhang, J., Mikuls, T. R., Saag, K., Yun, H., LaMoreaux, B., Francis-Sedlak, M., & Curtis, J. R. (2024). Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. https://doi.org/10.1002/acr.25361
Vancouver
Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, Saag K, et al. Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. 2024. doi:10.1002/acr.25361
BibTeX
@article{Holladay2024,
author = {Holladay, Emily E and Mudano, Amy S and Xie, Fenglong and Zhang, Jingyi and Mikuls, Ted R and Saag, Ken and Yun, Huifeng and LaMoreaux, Brian and Francis-Sedlak, Megan and Curtis, Jeffrey R},
title = {Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25361}
}
EUVIMED